A detailed history of Royal Bank Of Canada transactions in Atara Biotherapeutics, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 287,637 shares of ATRA stock, worth $2.22 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
287,637
Previous 30,495 843.23%
Holding current value
$2.22 Million
Previous $15,000 1220.0%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$0.44 - $1.22 $113,142 - $313,713
257,142 Added 843.23%
287,637 $198,000
Q4 2023

Feb 14, 2024

SELL
$0.23 - $1.74 $6,797 - $51,425
-29,555 Reduced 49.22%
30,495 $15,000
Q3 2023

Nov 14, 2023

BUY
$1.41 - $2.31 $11,777 - $19,295
8,353 Added 16.16%
60,050 $88,000
Q2 2023

Aug 14, 2023

BUY
$1.5 - $3.04 $9,081 - $18,404
6,054 Added 13.26%
51,697 $83,000
Q1 2023

May 15, 2023

BUY
$2.8 - $5.46 $56,140 - $109,473
20,050 Added 78.34%
45,643 $132,000
Q4 2022

Feb 14, 2023

BUY
$2.85 - $5.18 $17,912 - $32,556
6,285 Added 32.55%
25,593 $83,000
Q3 2022

Nov 14, 2022

SELL
$2.85 - $8.73 $894 - $2,741
-314 Reduced 1.6%
19,308 $73,000
Q2 2022

Aug 15, 2022

SELL
$4.69 - $9.84 $29,734 - $62,385
-6,340 Reduced 24.42%
19,622 $152,000
Q1 2022

May 16, 2022

BUY
$8.44 - $16.89 $17,023 - $34,067
2,017 Added 8.42%
25,962 $241,000
Q4 2021

Feb 14, 2022

BUY
$14.7 - $19.89 $153,276 - $207,393
10,427 Added 77.13%
23,945 $377,000
Q3 2021

Nov 15, 2021

SELL
$11.99 - $17.9 $1,234 - $1,843
-103 Reduced 0.76%
13,518 $242,000
Q2 2021

Aug 16, 2021

BUY
$12.89 - $16.58 $175,574 - $225,836
13,621 New
13,621 $212,000

Others Institutions Holding ATRA

About Atara Biotherapeutics, Inc.


  • Ticker ATRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,362,304
  • Market Cap $728M
  • Description
  • Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...
More about ATRA
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.